CSIR-IICT, NIIST, Suven Pharma join hands for COVID drug
A study published in the journal 'Nature Microbiology,' says that the drug can completely suppress the COVID virus transmission within 24 hours.
Press Trust of India | June 11, 2021 | 12:36 PM IST
Hyderabad: The CSIR-Indian Institute of Chemical Technology (IICT), Hyderabad, the CSIR-National Institute for Interdisciplinary Science and Technology (NIIST), Thiruvananthapuram and pharma company Suven Pharmaceuticals Ltd. (SPL) has entered into an MoU for the process technology transfer and manufacturing of the anti- COVID drug Molnupiravir.
The anti-viral drug was initially developed for the treatment of influenza and has been repurposed to treat COVID-19. According to a study published in the journal 'Nature Microbiology,' the drug can completely suppress the COVID virus transmission within 24 hours, the CSIR-IICT said in a release here on Thursday. The drug could be a game-changer in the mitigation of SARS-CoV-2 virus, it said.
"The antiviral drug was initially developed for the treatment of influenza and is repurposed to completely suppress the COVID virus transmission within 24 hours according to the study recently published in the Journal Nature Microbiology. The drug could be a game-changer in mitigation of SARS-CoV-2 virus," the release said.
The synthetic process know-how for Molnupiravir was sourced from CSIR-NIIST and the process to scale it up was successfully carried out by CSIR-IICT, it said. The complete technology know-how will be transferred to SPL and the company, in turn, would manufacture and launch the drug in the market as an effective medication for COVID infected patients, it said.
As per the agreement, CSIR-IICT would also provide the process know-how for the manufacture of new anti-COVID drug 2 -DG to treat moderate and severe COVID infected patients to reduce their oxygen dependency, the release added.
Write to us at news@careers360.com .
Follow us for the latest education news on colleges and universities, admission, courses, exams, research, education policies, study abroad and more..
To get in touch, write to us at news@careers360.com.
Next Story
]NEET panel in Tamil Nadu will give its report in a month, says Govt
The high-level committee led by retired judge of the Madras High Court, A K Rajan to study the impact of the National Eligibility-cum-Entrance Test on aspirants from the socially disadvantaged sections in medical admissions, Announcing the panel, the Chief Minister had said it would analyse if the national test had an adverse impact on students from backward classes and if it was so, the committee would recommend remedial measures.
Press Trust of IndiaFeatured News
]- ‘No two schools alike’: Experts challenge Bratya Basu’s fee control plan for West Bengal private schools
- CAG report on medical colleges: 23% faculty shortage at MAMC Delhi, Uttarakhand worse at 64%
- ‘Justice took 4 years’: How Vikrant Singh fought against IIT Guwahati and won
- ‘We’re being crushed’: Jadavpur University students demand election, accountability after minister car fiasco
- How Rajasthan stole the march on EV skilling under PM Kaushal Vikas Yojana
- Visa crackdown impact? 1.33 lakh fewer Indians pursuing overseas education, shows government data
- PM SHRI, NEP row: Education minister calls Tamil Nadu MPs ‘uncivilised’; DMK says ‘clearly stated issues’
- Rs 64.38 crore spent on Pariksha Pe Charcha while NTSE faces cuts: Education ministry data
- 4 years later, court calls IIT Guwahati scholar’s expulsion ‘arbitrary’; allows Vikrant Singh to complete PhD
- Game of Thrones on Gandhi Hills: Lessons from MGAHV Wardha’s years of turmoil